Effects of doxazosin as the third agent on morning hypertension and position-related blood pressure changes in diabetic patients with chronic kidney disease

• Published in: Clinical and experimental hypertension (1993) Vol. 37; no. 1; pp. 75 - 81
• Main Authors: Yasuda, Gen, Saka, Sanae, Ando, Daisaku, Hirawa, Nobuhito
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare USA, Inc 01.01.2015; Informa Healthcare
• Subjects: adrenergic antagonists; Aged; Aged, 80 and over; ambulatory blood pressure monitoring; Antihypertensive Agents - therapeutic use; Blood Pressure - drug effects; Blood Pressure Monitoring, Ambulatory - methods; Diabetes Mellitus; diabetic nephropathy; Doxazosin - therapeutic use; Female; Humans; Hypertension - complications; Hypertension - drug therapy; Male; Middle Aged; orthostatic hypotension; Posture - physiology; power spectral analysis; Prospective Studies; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - drug therapy; sympathetic nervous activity; ambulatory blood pressure monitoring; orthostatic hypotension; α1-adrenergic antagonists; power spectral analysis; diabetic nephropathy; sympathetic nervous activity
• ISSN: 1064-1963; 1525-6006
• DOI: 10.3109/10641963.2014.913599

Abstract We conducted a prospective study to assess the effects of doxazosin, as the third agent, on morning and position-related blood pressure (BP) in 77 diabetic patients with chronic kidney disease, who were allocated randomly to doxazosin and diuretics groups. Doxazosin decreased morning BP but diuretics could not decrease pre-awakening diastolic BP. Only doxazosin improved sympathovagal balance. Doxazosin and diuretics decreased standing and sitting BP but only doxazosin improved sympathovagal balance regardless of body positions. Doxazosin did not decrease absolute BP changes shortly after standing. In diabetic patients, doxazosin decreased morning BP through improving sympathovagal balance without causing significant orthostatic hypotension (ClinicalTrials.gov number, NCT00295555).